Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China’s National Medical Products Administration (NMPA) has officially accepted the marketing application for a new indication of Izalontamab Brengitecan (BL‑B01D1 / iza‑bren) for the treatment of unresectable or metastatic HR+/HER2‑ breast cancer in patients who have previously received endocrine therapy and at least one line of chemotherapy in the advanced disease setting.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Application Type | New Drug Application (NDA) – new indication; officially accepted |
| Product | Izalontamab Brengitecan (BL‑B01D1 / iza‑bren) |
| Indication Sought | Unresectable or metastatic HR+/HER2‑ breast cancer |
| Target Population | Adults pretreated with endocrine therapy and ≥ 1 line of chemotherapy in the advanced setting |
| Acceptance Date | 23 Oct 2026 |
| Supporting Data | Phase III trial BL‑B01D1‑306 – met primary PFS endpoint at prespecified interim analysis |
| Approved Indications to Date | Recurrent or metastatic nasopharyngeal carcinoma; recurrent or metastatic esophageal squamous cell carcinoma |
| Pending Reviews | Locally advanced or metastatic triple‑negative breast cancer (TNBC) – NDA accepted by CDE |
Drug Profile & Mechanism of Action
- Molecule: Izalontamab Brengitecan (BL‑B01D1) – an EGFR×HER3 bispecific antibody‑drug conjugate (ADC).
- Target: Dual engagement of EGFR and HER3, two receptor tyrosine kinases frequently co‑expressed and implicated in resistance across epithelial tumors, enabling broad tumor targeting with a single ADC construct.
- Modality: Bispecific ADC design intended to improve tumor selectivity and internalization versus single‑antigen ADCs, delivering a cytotoxic payload directly to antigen‑expressing cancer cells.
- Commercial Footprint: Already approved by the NMPA for two indications – recurrent or metastatic nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma – establishing BL‑B01D1 as a multi‑tumor‑type platform asset.
- Pipeline Breadth: With the HR+/HER2‑ breast cancer NDA acceptance and the CDE‑accepted TNBC indication under parallel review, Biokin is pursuing breast‑cancer expansion on two fronts alongside its approved head‑and‑neck and esophageal franchises.
Clinical Evidence – Phase III Trial (BL‑B01D1‑306)
| Endpoint | Result | Comparator | Relative Benefit |
|---|---|---|---|
| Progression‑Free Survival (PFS) – Primary Endpoint | Met at prespecified interim analysis | Not disclosed | Statistically positive (magnitude not disclosed) |
| Overall Survival | Not disclosed | Not disclosed | – |
| Objective Response Rate | Data not yet disclosed | Not disclosed | – |
| Safety Profile | Data not yet disclosed | – | – |
The registration‑enabling Phase III trial (protocol number BL‑B01D1‑306) met its primary endpoint of progression‑free survival in a prespecified interim analysis in patients with unresectable or metastatic HR+/HER2‑ breast cancer pretreated with endocrine therapy and at least one line of chemotherapy. Detailed efficacy magnitudes and safety data were not disclosed in the announcement.
Market Impact & Outlook
- Large Addressable Population: HR+/HER2‑ breast cancer is the most common breast cancer subtype, and patients progressing on endocrine therapy plus chemotherapy face limited options – positioning BL‑B01D1 in a high‑volume, high‑need line of therapy.
- ADC Momentum in Breast Cancer: The approval race in HER2‑low and HR+ breast cancer has validated ADCs as the dominant next‑wave modality; an EGFR×HER3 bispecific offers a mechanistically differentiated entry versus HER2‑directed incumbents.
- Multi‑Indication Platform Value: Each additional indication compounds revenue potential across oncology franchises – from nasopharyngeal and esophageal cancers (approved) to TNBC and now HR+/HER2‑ breast cancer (under review) – reinforcing BL‑B01D1 as Biokin’s core growth asset.
- Competitive Landscape: Biokin joins a crowded global race in ADC‑mediated breast cancer treatment; the Phase III PFS win strengthens its domestic first‑mover position in bispecific ADCs.
- Next Milestones: NMPA review and approval decision for the HR+/HER2‑ indication; CDE review outcome for TNBC. Timing not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory review timelines, approval outcomes, and commercial potential of Izalontamab Brengitecan (BL‑B01D1). Actual results may differ materially due to risks including regulatory review duration, final labeling, market adoption, reimbursement dynamics, and competition. NDA acceptance does not guarantee approval.-Fineline Info & Tech
